Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
| 対象疾患 | Melanoma |
|---|---|
| 相 | 第2相 |
| スポンサー | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| ステータス | 完了 |
| 参加者数 | 26 名 |
| 介入（薬剤） | Nivolumab |
| 開始日 | 2018年1月17日 |
| 完了日 | 2025年12月15日 |
| 結果公開日 | 2026年6月16日 |
概要
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Recurrence-free Survival
| Treatment (Nivolumab) | 87.8 percentage of participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)